Study S001559

A Multiple Dose Titration Study in Participants With Obesity or Overweight to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT05623839
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 32
Start: 2022-11-16
Primary completion: 2023-06-27
Lead sponsor: Eli Lilly and Company
Conditions: Overweight; Obesity
Interventions: DRUG:LY3305677; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:I8P-MC-OXAG

Registered primary outcomes

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 20]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013210	Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial. Bhattachar SN, Diabetes, obesity & metabolism	2025	Randomized trial	PMID 40832785 DOI	cites ClinicalTrials.gov:NCT05623839; registry reference DERIVED:40832785